S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
U.S. Military Defense Fails Without Vanadium? (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
U.S. Military Defense Fails Without Vanadium? (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
U.S. Military Defense Fails Without Vanadium? (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
U.S. Military Defense Fails Without Vanadium? (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
U.S. Military Defense Fails Without Vanadium? (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
U.S. Military Defense Fails Without Vanadium? (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
U.S. Military Defense Fails Without Vanadium? (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
U.S. Military Defense Fails Without Vanadium? (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund

NeoGenomics Stock Price, News & Analysis (NASDAQ:NEO)

$18.48
-0.61 (-3.20%)
(As of 12/5/2023 ET)
Compare
Today's Range
$18.34
$18.97
50-Day Range
$11.67
$19.51
52-Week Range
$8.70
$20.54
Volume
716,485 shs
Average Volume
972,525 shs
Market Capitalization
$2.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

NeoGenomics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
2.8% Upside
$19.00 Price Target
Short Interest
Bearish
4.93% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.68mentions of NeoGenomics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$49,083 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.35) to ($0.26) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.30 out of 5 stars

Medical Sector

889th out of 948 stocks

Testing Laboratories Industry

1st out of 1 stocks


NEO stock logo

About NeoGenomics Stock (NASDAQ:NEO)

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

NEO Stock Price History

NEO Stock News Headlines

All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
What 6 Analyst Ratings Have To Say About NeoGenomics
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
NeoGenomics Reports Third Quarter 2023 Results
Here's what Wall Street expects from Neogenomics's earnings report
NeoGenomics Inc NEO
Bull of the Day: NeoGenomics (NEO)
Where NeoGenomics Stands With Analysts
See More Headlines
Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/22/2024

Industry, Sector and Symbol

Industry
Testing laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NEO
Employees
2,100
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$19.00
High Stock Price Target
$25.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+2.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

Net Income
$-144,250,000.00
Pretax Margin
-18.67%

Debt

Sales & Book Value

Annual Sales
$509.73 million
Book Value
$7.90 per share

Miscellaneous

Free Float
125,809,000
Market Cap
$2.35 billion
Optionable
Optionable
Beta
1.32

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Christopher Michael Smith BSc (Age 60)
    CEO & Director
    Comp: $3.52M
  • Mr. Jeffrey S. Sherman M.B.A. (Age 57)
    Chief Financial Officer
    Comp: $492.31k
  • Mr. Vishal Sikri (Age 47)
    President of Advanced Diagnostics Division
    Comp: $1.21M
  • Mr. Warren Stone (Age 50)
    President of Clinical Division
    Comp: $722.79k
  • Ms. Cynthia J. Dieter (Age 48)
    Chief Accounting Officer
  • Mr. Greg Sparks
    Chief Technology Officer
  • Ms. Kendra Sweeney
    Vice President of Investor Relations & Communications
  • Ms. Alicia Olivo (Age 39)
    General Counsel & Corporate Secretary
  • Mr. Hutan Hashemi J.D. (Age 44)
    Chief Compliance Officer
  • Dr. Derek Lyle M.D.
    Chief Medical Officer














NEO Stock Analysis - Frequently Asked Questions

Should I buy or sell NeoGenomics stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NEO shares.
View NEO analyst ratings
or view top-rated stocks.

What is NeoGenomics' stock price target for 2024?

11 brokers have issued 1-year price objectives for NeoGenomics' stock. Their NEO share price targets range from $17.00 to $25.00. On average, they predict the company's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 2.8% from the stock's current price.
View analysts price targets for NEO
or view top-rated stocks among Wall Street analysts.

How have NEO shares performed in 2023?

NeoGenomics' stock was trading at $9.24 at the beginning of the year. Since then, NEO shares have increased by 100.0% and is now trading at $18.48.
View the best growth stocks for 2023 here
.

When is NeoGenomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our NEO earnings forecast
.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) issued its quarterly earnings data on Monday, November, 6th. The medical research company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.05. The medical research company earned $151.95 million during the quarter, compared to the consensus estimate of $142.15 million. NeoGenomics had a negative net margin of 16.76% and a negative trailing twelve-month return on equity of 4.95%.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics updated its FY 2023 earnings guidance on Monday, November, 6th. The company provided earnings per share (EPS) guidance of -$0.18--$0.15 for the period, compared to the consensus EPS estimate of -$0.28. The company issued revenue guidance of $585.00 million-$592.00 million, compared to the consensus revenue estimate of $573.19 million.

What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by many different institutional and retail investors. Top institutional investors include Brown Advisory Inc. (6.47%), Schroder Investment Management Group (1.97%), Emerald Advisers LLC (1.51%), Northern Trust Corp (1.24%), Emerald Mutual Fund Advisers Trust (1.22%) and Fred Alger Management LLC (1.04%). Insiders that own company stock include Alicia C Olivo, Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Lawrence Martin Weiss, Mark Mallon, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends
.

How do I buy shares of NeoGenomics?

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does NeoGenomics have any subsidiaries?
The following companies are subsidiares of NeoGenomics: Clarient Inc., Clarient Diagnostic Services Inc, Clarient Inc, Cynogen Inc., GE Medical Holding AB., Genesis Acquisition Holding Corp, Genesis Acquisition Holdings Corp., Genoptix, Genoptix Inc., Inivata Inc., Inivata Limited, Inivata Limited., Minuet Diagnostics Inc., NeoGenomics Bioinformatics Inc., NeoGenomics Europe SA, NeoGenomics Foundation Inc, NeoGenomics Laboratories Inc, NeoGenomics Singapore Pte. Ltd, Path Labs LLC, Suzhou NeoGenomics Pharmaceutical Research Co. Limited, Trapelo Health, and Trapelo Health LLC.
Read More
This page (NASDAQ:NEO) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -